7 results on '"A. Raja Choudhury"'
Number of results to display per page
Search Results
2. Hematopoietic Retroviral Gene Marking in Patients with Follicular Non-Hodgkin's Lymphoma
- Author
-
Deborah Ellerson, Richard E. Giles, Richard E. Champlin, Michael Andreeff, Fernando Cabanillas, Shelly Heimfeld, Albert B. Deisseroth, F. Garcia-Sanchez, Raja Choudhury, Ellie G. Hanania, Carlos Bachier, and Ronald J. Berenson
- Subjects
Adult ,Cancer Research ,Pathology ,medicine.medical_specialty ,Cyclophosphamide ,medicine.medical_treatment ,Genetic Vectors ,CD34 ,Antigens, CD34 ,Hematopoietic stem cell transplantation ,Biology ,Peripheral blood mononuclear cell ,Transduction, Genetic ,medicine ,Humans ,Lymphoma, Follicular ,Bone Marrow Transplantation ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Total body irradiation ,Hematopoietic Stem Cells ,medicine.disease ,Lymphoma ,Haematopoiesis ,Retroviridae ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Bone marrow ,medicine.drug - Abstract
We conducted a double retroviral vector (RV) gene marking trial to test for the possible contribution to relapse of follicular non-Hodgkin's lymphoma (FNHL) cells present in bone marrow (BM) and peripheral blood (PB) grafts used for hematopoietic reconstitution of patients undergoing myelaoblative chemotherapy and autologous transplant. CD34 positive selection using the CellPro Ceprate CD34 column was performed on PB mononuclear cells obtained after cyclophosphamide/G-CSF mobilization. CD34 positive cells were exposed for 4-6 hours to the LNL6 or G1 Na RV in the absence of growth factors or stromal monolayers. One week later, BM mononuclear cells were similarly processed. Patients then received total body irradiation (TBI), cyclophosphamide, and etoposide followed by infusion of both PB and BM CD34 positive cells. Semiquantitative Southern blot analysis of DNA t(14;18) amplification products showed approximately a three log reduction in t(14;18) positive cells after CD34 positive selection. The first patient showed evidence of engraftment with RV positive BM and PB cells for 9 months. He relapsed one year after transplant. At relapse, one year after transplant, he had lost evidence of RV positive cells in ficolled mononuclear BM and PB cells as well as in CD19 positive cells. The second and third patients showed evidence of engraftment with RV positive cells up to 9 and 6 months post BMT respectively. The second and third patients are still in clinical remission. Our results demonstrate engraftment of RV transduced hematopoietic cells in the PB and BM for up to 9 months.
- Published
- 1999
- Full Text
- View/download PDF
3. Defining the critical hurdles in cancer immunotherapy
- Author
-
Andrea Nicolini, Francesco M. Marincola, William E. Carson, Paolo A. Ascierto, Michele Maio, Jedd D. Wolchok, Michael T. Lotze, Jirina Bartunkova, Weihua Xiao, Hauke Winter, Barbara Seliger, Jon M. Wigginton, Cedrik M. Britten, Ignacio Melero, Guido Kroemer, Neil L. Berinstein, Jill O'Donnell-Tormey, Heinz Zwierzina, Lothar Bergmann, Lloyd J. Old, Christian H. Ottensmeier, Jérôme Galon, Per thor Straten, Koji Kawakami, Michael Papamichail, Yutaka Kawakami, Michael I. Nishimura, Mary L. Disis, Steinar Aamdal, C. J. M. Melief, Pedro Romero, Kristen Hege, Wenru Song, Pawel Kalinski, Jonathan L. Bramson, Harpreet Singh-Jasuja, Jens Peter Marschner, Bernard A. Fox, Samir N. Khleif, Brad H. Nelson, Marij J. P. Welters, Elizabeth M. Jaffee, Patrick Hwu, Rik J. Scheper, Robert C. Rees, Giuseppe Masucci, Hideaki Tahara, Cristina Bonorino, Glenn Dranoff, Ernest C. Borden, William J. Murphy, Zhigang Tian, Michael B. Atkins, Robert O. Dillman, Thomas F. Gajewski, Hiroshi Shiku, Leif Håkansson, Michael J. Mastrangelo, Lisa H. Butterfield, Shukui Qin, Laurence Zitvogel, Harry Dolstra, Michele Guida, George Coukos, Mohamed L. Salem, Xuetao Cao, Giorgio Parmiani, Enrico Proietti, Ena Wang, Sylvia Janetzki, A. Raja Choudhury, Gerd Ritter, Hyam I. Levitsky, Kunle Odunsi, Kohzoh Imai, Paul von Hoegen, Christoph Huber, Réjean Lapointe, Antoni Ribas, Dolores J. Schendel, Pamela S. Ohashi, Beatrix Kotlan, Cécile Gouttefangeas, James H. Finke, Alfred E. Chang, Howard L. Kaufman, Lindy G. Durrant, Sjoerd H. van der Burg, Jared Gollob, Dainius Characiejus, Tara Withington, Padmanee Sharma, Ronald B. Herberman, Cristina Maccalli, Ulrich Keilholtz, Axel Hoos, Graham Pawelec, Fabio Grizzi, Tanja D. de Gruijl, F. Stephen Hodi, Ruggero Ridolfi, James P. Allison, Licia Rivoltini, Carl H. June, Rolf Kiessling, Department of Molecular Microbiology and Immunology, Oregon Health and Science University [Portland] (OHSU)-Knight Cancer Institute, Earle A. Chiles Research Institute, Providence Portland Medical Center-Robert W. Franz Research Center-Providence Cancer Center, Clinical Cooperation Group 'Immune Monitoring', German Research Center for Environmental Health-Helmholtz Centre Munich-Institute of Molecular Immunology, Division of Hematology Oncology, University of Pittsburgh Cancer Institute-Departments of Medicine, Department of Surgery, Cancer Institute-University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE)-Pennsylvania Commonwealth System of Higher Education (PCSHE), Department of Immunology, University of Pittsburgh Cancer Institute, Department of Clinical Cancer Research, The Norwegian Radium Hospital-Oslo University Hospital [Oslo], Memorial Sloane Kettering Cancer Center [New York], Howard Hughes Medical Institute (HHMI), Medical Oncology and Innovative Therapy, Instituto Nazionale Tumori-Fondazione 'G. Pascale', Beth Israel Deaconess Medical Center, Harvard Medical School [Boston] (HMS), Institute of Immunology, Charles University [Prague] (CU)-FOCIS Center of Excellence-2nd Medical School, Goethe-Universität Frankfurt am Main, IRX Therapeutics, Stanford University-ImmunoVaccine Inc., Instituto Nacional para o Controle do Câncer, Instituto de Pesquisas Biomédicas-PUCRS Faculdade de Biociências, Department of Solid Tumor Oncology, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Department of Pathology, McMaster University [Hamilton, Ontario], University Medical Center Mainz, III. Medical Department, Ribological GmbH, Department of Medicine-University Medical Center of the Johannes Gutenberg-University-Clinical Development, BioNTech AG, Chinese Academy of Medical Sciences, Second Military Medical University-National Key Laboratory of Medical Immunology, Ohio State University [Columbus] (OSU), University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Institute of Oncology, Vilnius University [Vilnius]-Faculty of Medicine, Department of Medicine, University of Queensland [Brisbane], Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania [Philadelphia]-University of Pennsylvania [Philadelphia], Department of Medical Oncology, VU Medical Center-Cancer Center Amsterdam, Hoag Institute for Research and Education, Hoag Cancer Institute, Department of Laboratory Medicine, Radboud university [Nijmegen]-Nijmegen Centre for Molecular Life Sciences-Nijmegen Medical Centre [Nijmegen], Brigham and Women's Hospital [Boston], Dana-Farber Cancer Institute [Boston], Academic Department of Clinical Oncology, University of Nottingham, UK (UON), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Alnylam Pharmaceuticals, Inc., Institute for Cell Biology, Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Oncology Department, University of Lund, CanImGuide Therapeutics AB, University of California [San Francisco] (UCSF), University of California, Intrexon Corporation, Germantown, Bristol-Myers Squibb Company, Translational Oncology & Immunology, Centre TRON at the Mainz University Medical Center, Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center [Houston], The Institute of Medical Science, The University of Tokyo (UTokyo), Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine [Baltimore]-Johns Hopkins University School of Medicine [Baltimore], ZellNet Consulting, Pathology and Laboratory Medicine, University of Pennsylvania [Philadelphia], Rush University Cancer Center, Rush University Medical Center [Chicago], School of Medicine and Public Health, Kyoto University [Kyoto], Division of Cellular Signaling, Institute for Advanced Medical Research, Dept. of Hematology and Medical Oncology, Charité Comprehensive Cancer Center, Cancer Vaccine Section, NCI, Department of Oncology - Pathology, Cancer Center Karolinska [Karolinska Institutet] (CCK), Karolinska Institutet [Stockholm]-Karolinska Institutet [Stockholm], Department of Molecular Immunology and Toxicology, Center of Surgical and Molecular Tumor pathology, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), School of Medicine, Johns Hopkins University (JHU)-Oncology Center, Department of Molecular Oncology, Foundation San Raffaele Scientific Institute, Medical Oncology and Immunotherapy, Istituto Toscano Tumori-University Hospital of Siena-Department of Oncology, Merck KGaA, Merck & Co. Inc, Thomas Jefferson University, Department of Oncology-Pathology, karolinska institute, CIMA, CUN and Medical School University of Navarra, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), Davis Medical Center, Sacramento-University of California, Deeley Research Centre, BC Cancer Agency (BCCRC), Department of Internal Medicine, University of Pisa - Università di Pisa, Oncology Institute, Loyola University Medical Center (LUMC)-Cardinal Bernardin Cancer Center, Tumor Immunology and Immunotherapy Program, Roswell Park Cancer Institute [Buffalo]-Department of Gynecologic Oncology, Ontario Cancer Institute, University Health Network, Cancer Immunotherapy Consortium (CIC), Cancer Research Institute, Cancer Research, Ludwig Institute, Experimental Cancer Medicine Centre, University of Southampton-Faculty of Medicine, Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, San Raffaele Scientific Institute, Center for Medical Research, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita', Chinese PLA Cancer Center, Department of Oncology-The Eighty-First Hospital, The John van Geest Cancer Research Centre, School of Science and Technology-Nottingham Trent University, Jonsson Comprehensive Cancer Center, Immunoterapia e Terapia Cellulare Somatica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori-IRCCS Foundation, Division of Clinical Onco-Immunology, Université de Lausanne (UNIL)-Ludwig Center for Cancer Research, Immunology and Biotechnology Unit, Faculty of Science-Department of Zoology-Tanta University, VU University Medical Center [Amsterdam], Institute of Medical Immunology, Martin-Luther-Universität Halle Wittenberg (MLU), Departments of Immunology, Department of Cancer Vaccine, Mie University, Department of Immuno-gene Therapy, Immatics Biotechnologies GmbH, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen-Department of Immunology-Institute for Cell Biology, Millennium: The Takeda Oncology Company, Pfizer Oncology, Center for Cancer Immune Therapy (CCIT), Herlev and Gentofte Hospital-Department of Hematology, Department of Surgery and Bioengineering, The University of Tokyo (UTokyo)-Institute of Medical Science-Advanced Clinical Research Center, School of Life Sciences-University of Science & Technology of China [Suzhou], Institute of Immunopharmacology & Immunotherapy, Shandong University-School of Pharmaceutical Sciences, Experimental Cancer Immunology and Therapy, Leiden University Medical Center (LUMC)-Department of Clinical Oncology, Euraccine Consulting Group, Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine-Clinical Center-National Institute of Health NIH), Center for Human Immunology (CHI), National Institute of Health (NIH), Leiden University Medical Center (LUMC)-Department of Clinical Oncology (K1-P), Ludwig Maximilians University-Klinikum Grosshadern, Biological Therapy of Cancer, Medical and Surgical Services Organizations-International Society For Biological Therapy Of Cancer, School of Life Science-University of Science and Technology of China [Hefei] (USTC), Immunologie des tumeurs et immunothérapie (UMR 1015), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Department Haematology and Oncology, Innsbruck Medical University [Austria] (IMU), Medical Center, University of Chicago, Discovery Medicine-Oncology, Tumor Vaccine Group, University of Washington [Seattle]-Center for Translational Medicine in Women's Health, The work of CIMT-CIP was supported by a grant from the Wallace Coulter foundation (Florida, USA)., Helmholtz Centre Munich-Institute of Molecular Immunology-Helmholtz Zentrum München = German Research Center for Environmental Health, University of Pennsylvania-University of Pennsylvania, Radboud University [Nijmegen]-Nijmegen Centre for Molecular Life Sciences-Nijmegen Medical Centre [Nijmegen], Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Lund University [Lund], University of California [San Francisco] (UC San Francisco), University of California (UC), University of Pennsylvania, Kyoto University, Sacramento-University of California (UC), Université de Lausanne = University of Lausanne (UNIL)-Ludwig Center for Cancer Research, Klinikum Grosshadern-Ludwig-Maximilians University [Munich] (LMU), University of Science and Technology of China [Hefei] (USTC)-School of Life Science, Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), BMC, Ed., Computer Systems, Medical oncology laboratory, Pathology, CCA - Immuno-pathogenesis, CCA - Innovative therapy, Oregon Health and Science University-Knight Cancer Institute, Cancer Institute-University of Pittsburgh, The Norwegian Radium Hospital-Oslo University Hospital, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, Howard Hughes Medical Institute, Ludwig Center for Cancer Immunotherapy, A Teaching Hospital of Harvard Medical School, Charles University [Prague]-FOCIS Center of Excellence-2nd Medical School, Stanford University [Stanford]-ImmunoVaccine Inc., Ohio State University [Columbus] ( OSU ), University of Michigan Medical Center, University of Pennsylvania Medical Center, Radboud university [Nijmegen]-Nijmegen Centre for Molecular Life Sciences-Nijmegen Medical Centre, University of Nottingham, UK ( UON ), Cleveland Clinic Foundation, Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Istituto Clinico Humanitas [Milan] ( IRCCS Milan ), Humanitas University [Milan] ( Hunimed ), University of California [San Francisco] ( UCSF ), Harvard Medical School [Boston] ( HMS ), MD Anderson Cancer Center, The University of Tokyo, Rush University Medical Center, Cancer Center Karolinska [Karolinska Institutet] ( CCK ), Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame Research Center ( CRCHUM ), Department of Medicine-University of Montreal, Johns Hopkins University ( JHU ) -Oncology Center, BC Cancer Agency ( BCCRC ), University of Pisa [Pisa], Loyola University Medical Center ( LUMC ) -Cardinal Bernardin Cancer Center, Cancer Immunotherapy Consortium ( CIC ), University of Southampton [Southampton]-Faculty of Medicine, Eberhard Karls Universität Tübingen, University of Lausanne-Ludwig Center for Cancer Research, Martin-Luther-University Halle-Wittenberg, Mie University Graduate School of Medicine, Eberhard Karls Universität Tübingen-Department of Immunology-Institute for Cell Biology, Center for Cancer Immune Therapy ( CCIT ), Herlev Hospital-Department of Hematology, The University of Tokyo-Institute of Medical Science-Advanced Clinical Research Center, Infectious Disease and Immunogenetics Section ( IDIS ), Center for Human Immunology ( CHI ), University of Science and Technology of China [Hefei] ( USTC ) -School of Life Science, Immunologie des tumeurs et immunothérapie ( UMR 1015 ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Innsbruck Medical University [Austria] ( IMU ), Department of Medicine-Clinical Development, BioNTech AG-Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Universiteit Leiden-Universiteit Leiden, Roswell Park Cancer Institute [Buffalo] (RPCI)-Department of Gynecologic Oncology, Istituto Superiore di Sanità (ISS), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Universiteit Leiden-Universiteit Leiden-Department of Clinical Oncology, and Universiteit Leiden-Universiteit Leiden-Department of Clinical Oncology (K1-P)
- Subjects
medicine.medical_specialty ,International Cooperation ,medicine.medical_treatment ,Alternative medicine ,lcsh:Medicine ,Translational research ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cancer Immunotherapy ,General Biochemistry, Genetics and Molecular Biology ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Translational Research, Biomedical ,03 medical and health sciences ,SDG 17 - Partnerships for the Goals ,0302 clinical medicine ,Cancer immunotherapy ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology ,Neoplasms ,medicine ,Humans ,In patient ,030304 developmental biology ,Medicine(all) ,0303 health sciences ,geography ,Summit ,geography.geographical_feature_category ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Biochemistry, Genetics and Molecular Biology(all) ,business.industry ,lcsh:R ,Cancer ,General Medicine ,Public relations ,medicine.disease ,3. Good health ,Clinical trial ,Immunotherapy ,Neoplasms/therapy ,Translational Medical Research ,030220 oncology & carcinogenesis ,Immunology ,Commentary ,Working group ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.
- Published
- 2011
- Full Text
- View/download PDF
4. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer
- Author
-
Koji, Kono, Akihiro, Takahashi, Hidemitsu, Sugai, Hideki, Fujii, A Raja, Choudhury, Rolf, Kiessling, and Yoshiro, Matsumoto
- Subjects
Adult ,Male ,Time Factors ,CA-19-9 Antigen ,Receptor, ErbB-2 ,T-Lymphocytes ,Dendritic Cells ,Middle Aged ,Transfection ,Cancer Vaccines ,Immunohistochemistry ,Carcinoembryonic Antigen ,Epitopes ,Stomach Neoplasms ,HLA-A2 Antigen ,Leukocytes, Mononuclear ,Humans ,Peptides ,Aged - Abstract
We have previously reported (K. Kono et al., Int. J. Cancer, 78: 202-208, 1998) that HER-2/neu-derived peptides are naturally processed as tumor-associated antigens recognized by tumor-specific, human leukocyte antigen (HLA)-A2-restricted CTLs in gastric cancer. In the present study, we described a Phase-1 vaccination trial in gastric cancer patients using dendritic cells (DCs) pulsed with the immunodominant HER-2/neu(p369) peptides.Nine enrolled patients, who had HER-2/neu-overexpressing tumors and who were HLA-A2 positive, received four vaccinations by DCs pulsed with HER-2(p369) peptide at 2-week intervals intradermally.There were no serious adverse effects noted in the immunized patients. Peripheral blood mononuclear cells, preimmunization and after the fourth immunization, were cultured with autologous, HER-2(p369)-pulsed antigen-presenting cells for 12 days. Thereafter, peptide specificity was evaluated by IFN-gamma secretion assay from cultured T cells against T2 cells pulsed with HER-2(p369) peptide. HER-2/neu peptide-specific recognition could be demonstrated in six of nine patients after immunization, whereas there was no HER-2/neu peptide-specific recognition before immunization. The peptide-specific CTL lines isolated from two of the patients could also lyse a HER2/neu-transfected cell line. Furthermore, a peptide-specific delayed-type hypersensitivity response occurred in three of nine patients. One of the patients underwent a partial clinical response concurrent with a decrease of tumor marker. Another patient demonstrated a stabilization of disease status for a period of 3 months.Taken together, tumor vaccination therapy with DCs pulsed with HER-2/neu-peptides may be a potential candidate for the novel treatment of gastric cancer patients.
- Published
- 2002
5. Defining the critical hurdles in cancer immunotherapy
- Author
-
Fox, BA, Schendel, DJ, Butterfield, LH, Aamdal, S, Allison, JP, Ascierto, PA, Atkins, MB, Bartunkova, J, Bergmann, L, Berinstein, N, Bonorino, CC, Borden, E, Bramson, JL, Britten, CM, Cao, X, Carson, WE, Chang, AE, Characiejus, D, Raja Choudhury, A, Coukos, G, de Gruijl, T, Dillman, RO, Dolstra, H, Dranoff, G, Durrant, LG, Finke, JH, Galon, J, Gollob, JA, Gouttefangeas, C, Grizzi, F, Guida, M, Håkansson, L, Hege, K, Herberman, RB, Stephen Hodi, F, Hoos, A, Huber, C, Hwu, P, Imai, K, Jaffee, EM, Janetzki, S, June, CH, Kalinski, P, Kaufman, HL, Kawakami, K, Kawakami, Y, Keilholtz, U, Khleif, SN, Kiessling, R, Kotlan, B, Kroemer, G, Lapointe, R, Levitsky, HI, Lotze, MT, Maccalli, C, Maio, M, Marschner, JP, Mastrangelo, MJ, Masucci, G, Melero, I, Melief, C, Murphy, WJ, Nelson, B, Nicolini, A, Nishimura, MI, Odunsi, K, Ohashi, PS, O'Donnell-Tormey, J, Old, LJ, Ottensmeier, C, Papamichail, M, Parmiani, G, Pawelec, G, Proietti, E, Qin, S, Rees, R, Ribas, A, Ridolfi, R, Ritter, G, Rivoltini, L, Romero, PJ, Salem, ML, Scheper, RJ, Seliger, B, Sharma, P, Shiku, H, Singh-Jasuja, H, Song, W, Straten, PT, Tahara, H, Tian, Z, van der Burg, SH, von Hoegen, P, Wang, E, Welters, MJP, Winter, H, Withington, T, Wolchok, JD, Xiao, W, Zitvogel, L, Fox, BA, Schendel, DJ, Butterfield, LH, Aamdal, S, Allison, JP, Ascierto, PA, Atkins, MB, Bartunkova, J, Bergmann, L, Berinstein, N, Bonorino, CC, Borden, E, Bramson, JL, Britten, CM, Cao, X, Carson, WE, Chang, AE, Characiejus, D, Raja Choudhury, A, Coukos, G, de Gruijl, T, Dillman, RO, Dolstra, H, Dranoff, G, Durrant, LG, Finke, JH, Galon, J, Gollob, JA, Gouttefangeas, C, Grizzi, F, Guida, M, Håkansson, L, Hege, K, Herberman, RB, Stephen Hodi, F, Hoos, A, Huber, C, Hwu, P, Imai, K, Jaffee, EM, Janetzki, S, June, CH, Kalinski, P, Kaufman, HL, Kawakami, K, Kawakami, Y, Keilholtz, U, Khleif, SN, Kiessling, R, Kotlan, B, Kroemer, G, Lapointe, R, Levitsky, HI, Lotze, MT, Maccalli, C, Maio, M, Marschner, JP, Mastrangelo, MJ, Masucci, G, Melero, I, Melief, C, Murphy, WJ, Nelson, B, Nicolini, A, Nishimura, MI, Odunsi, K, Ohashi, PS, O'Donnell-Tormey, J, Old, LJ, Ottensmeier, C, Papamichail, M, Parmiani, G, Pawelec, G, Proietti, E, Qin, S, Rees, R, Ribas, A, Ridolfi, R, Ritter, G, Rivoltini, L, Romero, PJ, Salem, ML, Scheper, RJ, Seliger, B, Sharma, P, Shiku, H, Singh-Jasuja, H, Song, W, Straten, PT, Tahara, H, Tian, Z, van der Burg, SH, von Hoegen, P, Wang, E, Welters, MJP, Winter, H, Withington, T, Wolchok, JD, Xiao, W, and Zitvogel, L
- Abstract
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.
- Published
- 2011
6. Black holes, time bandits and the gentleman's code
- Author
-
Ranjit Raja Choudhury
- Subjects
Philosophy ,Law ,media_common.quotation_subject ,Art history ,Dream ,Adventure ,General Business, Management and Accounting ,Code (semiotics) ,media_common - Abstract
“As people grow older, the world they like to think of as dream, in contrast to the world they would like to think of as tangible reality, becomes dominant. As one fades, the other becomes more brightly illuminated. Quite unobtrusively one merges into the other, just as the smell of oranges, perceptible in the pantomime gallery, permeating the dress circle and penetrating even to the stalls bar, is apt to do so in the really-real-world of pantomime”. (Professor Gordon Pask from the “Adventures with Professor Flaxman-Low”, 1992)
- Published
- 2007
- Full Text
- View/download PDF
7. T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities
- Author
-
Håkan Mellstedt, Marzia Palma, Fariba Mozaffari, Parviz Kokhaei, Eva Rossmann, Anders Österborg, and A. Raja Choudhury
- Subjects
CD40 ,biology ,business.industry ,Chronic lymphocytic leukemia ,medicine.medical_treatment ,T cell ,Immunology ,Cell ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Peripheral blood mononuclear cell ,medicine.anatomical_structure ,Cytokine ,Apoptosis ,hemic and lymphatic diseases ,medicine ,Cancer research ,biology.protein ,business ,CD8 - Abstract
Background: Multiple T cell abnormalities in Chronic Lymphocytic Leukemia (CLL) patients are well established. Compared to healthy individuals, total T lymphocyte count, CD8+ cells and CD4+ cells in CLL patients are increased and follow disease activity, i.e. increase at CLL progression. Major alterations in T cell functions and TCR repertoire have also been reported as well as T cells specifically recognizing the leukemic CLL cells. It may be hypothesized that aberrantly functioning T cells contribute to a microenvironment which may allow CLL cells to avoid apoptosis and/or support the proliferative capacity. However, the underlying mechanisms are largely unknown. Materials and Methods: T cells and CLL cells were highly purified from PBMC of 20 patients with indolent CLL as well as normal blood B- and T-cells from healthy control donors (n=7). Autologous T cells and B cells were co-cultured at different T:B ratios for 72 h in ordinary and transwell plates. Apoptosis of B cells were assayed using Annexin-V and supernatants were analysed by Luminex for the following cytokines: RANTES, IL-10, IL-8, TNF-α, IFN-γ, IL-4, MCP-1, CD40L and GM-CSF. Results: Apoptosis of CLL cells was significantly (p Conclusions: Our data provide proof-of-principle that autologous T cells prevent apoptosis of CLL cells in a dose-dependent fashion and the effect was critically dependent on cell:cell contact. A number of cytokine candidates were identified for further studies. The results provide a basis for exploring therapeutic approaches aiming at selective inhibition/depletion of T cells in patients with CLL.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.